Adlai Nortye (ANL) Total Current Liabilities (2022 - 2025)
Adlai Nortye's (ANL) quarterly Total Current Liabilities came in at $41.6 million in Q4 2025, down 8.23% year-on-year from $45.4 million in Q4 2024, and down 34.82% on a QoQ basis from $63.9 million in Q2 2025.
Adlai Nortye (ANL) Total Current Liabilities (2022 - 2025) Analysis & Trends
Adlai Nortye (ANL) has 4 years of Total Current Liabilities data on file, last reported at $41.6 million in Q4 2025.
- On a quarterly basis, Total Current Liabilities fell 8.23% year-over-year to $41.6 million in Q4 2025; TTM through Dec 2025 was $41.6 million, a 8.23% decrease from a year earlier, with the FY2025 full-year figure at $41.6 million, down 8.23% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $41.6 million, down from $63.9 million in the prior quarter.
- Over the last five years, Total Current Liabilities for ANL reached as high as $312.7 million in Q4 2022 and fell as low as $41.6 million in Q4 2025.
- Historically, Total Current Liabilities has averaged $94.6 million across 4 years, with a median of $52.0 million in 2023.
- Across the five-year window, Total Current Liabilities slumped 84.11% in 2023 and rose 17.59% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $312.7 million in 2022, then slumped by 84.11% to $49.7 million in 2023, then slipped by 8.68% to $45.4 million in 2024, then retreated by 8.23% to $41.6 million in 2025.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $41.6 million in Q4 2025, $63.9 million in Q2 2025, and $45.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 289.60 Mn |
| 10 | Adlai Nortye | 1.16 Bn | 1.15 Bn | - | 41.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.63 Mn |
| Jun 30, 2025 | 63.87 Mn |
| Dec 31, 2024 | 45.36 Mn |
| Jun 30, 2024 | 54.31 Mn |
| Dec 31, 2023 | 49.67 Mn |
| Dec 31, 2022 | 312.65 Mn |